PharmaInformatic´s Knowledge Bases on ADME and Toxicology PharmaInformatic develops and licenses ADME/Tox knowledge bases for pharmaceutical research to optimize and accelerate drug discovery and development. We have currently launched PACT-F, the largest knowledge base on bioavailability worldwide. PACT-F contains experimental bioavailability results of clinical trials in humans and preclinical trials in animals. The results and conditions of those trials have been taken manually from more than 8100 scientific research articles related to bioavailability.            The development of PACT-F commenced in 2005. PACT-F is now the largest knowledge base on bioavailability worldwide. It contains more than 28.000 data records, which describe in detail the results of clinical trials in humans and preclinical trials in animals. PACT-F has been used to develop computational models to predict human oral bioavailability. The performance and quality of those models, validated with large, independent and diverse set of drugs, was shown to be remarkably better compared to animal trials. The expert system to predict oral bioavailability in humans is now available for licensing (see IMPACT-F). PharmaInformatic has created a large and comprehensive annotated knowledge base on plasma protein binding (PPB-DB). It currently contains more than 7.200 diverse compounds. This knowledge is now used to develop in silico models which evaluate plasma protein binding by analysing the compound structure with artificial intelligence. A validation study containing a large number of independent substances demonstrated a high quality of prediction (low error and high correlation between experimental and predicted plasma protein binding values).   Frequently Asked Questions (FAQ): Can IMPACT-F predict human oral bioavailability of entirely new molecules? Is IMPACT-F restricted to a specific therapeutic area, such as CNS therapeutics? What is required to predict oral bioavailability with IMPACT-F?

LEAD
OPTIMIZATION
with
IMPACT-F:

==> selects oral bioavailable
drugs

==> increases efficacy of clinical trials

==> results
directly available

Only compound structure needed
==> no further assays, synthesis
 or costs